{"id":"W4391720973","doi":"10.1016/j.prdoa.2024.100239","title":"Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance","year":2024,"lang":"en","type":"article","venue":"Clinical Parkinsonism & Related Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Cégep de Lévis","funders":"Parkinsonfonden; LEO Pharma; Sun Pharma; Göteborgs Universitet; Sahlgrenska Universitetssjukhuset; University of Washington; Sage Therapeutics; Neurocrine Biosciences; Acorda Therapeutics; Ipsen; Jazz Pharmaceuticals; EVER Neuro Pharma; Michael J. Fox Foundation for Parkinson's Research; Revance; Boston Scientific Corporation; H. Lundbeck A/S; Sunovion; Washington State University; Parkinson's Foundation; Amneal Pharmaceuticals; Biogen; Pfizer; Northwestern University; F. Hoffmann-La Roche; Massachusetts General Hospital; Neuraxpharm; Teva Pharmaceutical Industries; US WorldMeds; Allergan; AstraZeneca; Eli Lilly and Company; Supernus Pharmaceuticals; AbbVie; Sanofi","keywords":"Medicine; Adverse effect; Dopaminergic; Intensive care medicine; Disease; Deep brain stimulation; Parkinson's disease; Physical medicine and rehabilitation; Internal medicine; Dopamine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00298286,0.0003292161,0.001034188,0.000682632,0.0002012095,0.001154737,0.000681726,0.001042599,0.001370716],"category_scores_gemma":[0.004906733,0.0001553506,0.001053491,0.000494905,0.0005012436,0.00121933,0.0003125923,0.001790659,0.0004945829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000837362,"about_ca_system_score_gemma":0.001777302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001063891,"about_ca_topic_score_gemma":0.002904994,"domain_scores_codex":[0.9987705,0.0004719268,0.0003263798,0.00009493186,0.0002980419,0.00003817876],"domain_scores_gemma":[0.9968089,0.001918712,0.0006566296,0.0000534472,0.000467233,0.00009498345],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006243485,0.0000986017,0.0006096721,0.02442276,0.0002609385,0.0006355234,0.0001302455,0.0005017392,0.002134134,0.002511349,0.01578707,0.9522836],"study_design_scores_gemma":[0.001207035,0.003714747,0.008675744,0.08325406,0.002534298,0.01342422,0.0005045455,0.002051194,0.004549202,0.008498902,0.8714271,0.0001589926],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"methods","genre_scores_codex":[0.001398093,0.9915968,0.001191548,0.003603014,0.0002899588,0.00005509653,0.00003447668,0.00002342082,0.001807649],"genre_scores_gemma":[0.0257836,0.960705,0.007335356,0.003770007,0.001254619,0.000189985,0.0000958236,0.00001746994,0.0008481542],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.00298286,"threshold_uncertainty_score":0.01577502,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02982233691540017,"score_gpt":0.3244813869106378,"score_spread":0.2946590499952377,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}